Navigation Links
Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009
Date:3/27/2009

SHENZEN, China, March 27 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com Today after the market closed the company announced the clinical trial protocol for their MMR Vaccine is under preparation, and is expected to be approved by the end of the second quarter 2009.

The MMR Vaccine is a mixture of three live attenuated viruses administered via injection for immunization against measles, mumps, and rubella (also called German measles). It is generally administered to children around the age of one year, with a second dose before starting school (i.e. age 4/5).

Prior to the widespread use of a vaccine against measles, its incidence was so high that infection was felt to be inevitable. Today, it is widely used around the world, and since introduction of its earliest versions in the 1970s, more than 500 million doses have been administered in over 60 countries. The incidence rate has fallen to a low of less than 1% of people under the age of 30 in countries with routine childhood vaccination.

The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, readers should contact the company directly at corporate@htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Microsurgery May Cut Swelling After Breast Cancer Treatment
2. Treatment Target for Herpes Pinpointed
3. Plastic Surgeon Allan Parungao, MD, FACS, Announces Clinical Trial of Juvderm Technique to Treat Root Cause of Midface Sagging, without Surgery
4. Individualized stroke treatment available for patients, though underutilized
5. New Guidelines for Treating Heart Failure
6. New OTC Allergy Treatment Available to Food Allergy Sufferers
7. Combating weight gain caused by antipsychotic treatments
8. Autism Study Finds Significant Benefit with Hyperbaric Treatment
9. NeuroVasx Receives CE Mark for cPAX Aneurysm Treatment System
10. Surveyed Experts Indicate that Biogen Idecs Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure
11. Autism Website Relaunches to Offer Resources, Treatments and Hope for Families
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , ... January 16, 2017 , ... ... been appointed Chief Executive Officer of the medical device company, effective immediately. , ... Robert Storey. “Kevin has a strong track record in medical device market ...
(Date:1/15/2017)... , ... January 15, 2017 , ... In this role, ... the United States for the asthma & allergy friendly mark. This certification program was ... test and identify consumer products to be more suitable for the 60+ million people ...
(Date:1/15/2017)... ... 2017 , ... Whole Health Supply, LLC is announcing the release of an updated version of ... purchase. , The 2017 edition has wide jaws that will accommodate nails up to ... well as diabetics. This handle is reinforced for extra strength when pressing down on dense ...
(Date:1/15/2017)... ... January 15, 2017 , ... "On Tour is a music ... customization and ease," said Christina Austin - CEO of Pixel Film Studios. , ... can edit the style and animation of their slideshows. Place each slide on top ...
(Date:1/15/2017)... ... ... Wondering where to go this Valentine's Day? Well, there is a solution to ... feast in the comfort of your own home. Lobster Gram is introducing two new ... until February 15th, 2017. , Romantic Dinner one is Lobster Gram's "Love at ...
Breaking Medicine News(10 mins):
(Date:1/14/2017)... , Jan. 14, 2017  Johnson & Weaver, LLP announces ... purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ... October 31, 2016 (the "Class Period"). Zimmer Biomet ... markets orthopaedic reconstructive products, such as knee and hip reconstructive ... ...
(Date:1/13/2017)... , January 13, 2017 Stock-Callers is ... Medical Group N.V. (NASDAQ: WMGI ), Varian Medical ... (NASDAQ: MDXG ), and NuVasive Inc. (NASDAQ: ... which fell back to a negative finish on Thursday, January ... falling about 0.1%, while shares of health care companies in ...
(Date:1/13/2017)...  Alfalfa, cattle, leafy greens and rosy cheeked children share ... which emphasizes the food industry,s shift from response to prevention. ... COPAN,s Swab Rinse Kit (SRK™) is ... in the wake of the new FDA Food Safety ... is expanding the U.S. production of the SRK line ...
Breaking Medicine Technology: